COIOSDeep risk insights through multi-disciplinary research across the globe
a room with a plant and some lights
Item refines Preprint · not peer-reviewed Added

GLP-1 drugs lower stroke risk by 17%, little of it explained by blood pressure

A meta-analysis of seven randomised trials in type 2 diabetes found that GLP-1 receptor agonists lowered stroke risk by 17%, with blood pressure lowering explaining about a quarter of it.

Seven randomised trials with prespecified, adjudicated stroke endpoints were pooled, covering 50,617 adults with type 2 diabetes at high cardiovascular risk. Stroke risk was 17% lower on a GLP-1 receptor agonist, while the difference in blood pressure between arms would predict only 4%. In four further trials, in people already living with a neurodegenerative disease, memory and thinking did not improve.

Why it is interesting: Most of the stroke benefit is unexplained by blood pressure, blood glucose or weight loss.

Source
medRxiv, 21 September 2026
Paper
GLP-1 Receptor Agonists, Stroke, and Cognitive Outcomes: Systematic Review and Meta-Regression
Authors
Danielli M, Sibal R, Collett G, Awan H, Sharma C, Steckelmacher J et al.
DOI
10.64898/2026.09.18.26363449
Type
Preprint
Design
Systematic review and meta-regression of 7 RCTs with adjudicated stroke endpoints (n=50,617), plus narrative synthesis of 4 cognitive trials (n=4,206), to August 2026
Verdict
Refines prior evidence
Driver
Heart and stroke
Driver
Obesity, diabetes and GLP-1

Other drivers in Health today